Business Context and Reporting Period
Company: Novo Nordisk A/S
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2003
Business Overview: A focused healthcare company and world leader in diabetes care, with additional leading positions in hemostasis management, growth hormone therapy, and hormone replacement therapy. The company operates two segments: Diabetes Care and Biopharmaceuticals.
Accounting Basis: Financial statements prepared under Danish GAAP, with reconciliations to US GAAP provided. The company plans to adopt IFRS effective January 1, 2004.
Key Financial Metrics
Revenue and Profit:
- Net Turnover (2003): DKK 26.5 billion (up 5% reported; up 15% in local currencies).
- Operating Profit (2003): DKK 6.4 billion (up 7% reported).
- Net Profit (US GAAP): Increased 15% compared to 2002.
- Net Profit (Danish GAAP): DKK 4,858 million.
- Gross Margin: 72% (down from 74% in 2002, impacted by currency and production costs).
- Operating Margin: 24% (up from 22% in 1999).
- Diabetes Care Segment Margin: 17%.
- Biopharmaceuticals Segment Margin: 42%.
- Free Cash Flow (2003): DKK 3,846 million (significant increase from DKK 497 million in 2002).
- Cash and Cash Equivalents: DKK 2,669 million.
- Undrawn Committed Credit Facilities: DKK 8,701 million.
- Long-term Debt: DKK 753 million.
- Net Capital Expenditure (2003): DKK 2.3 billion (down from DKK 4.0 billion in 2002 due to completion of major facilities).
- 2004 Investment Outlook: Approximately DKK 3.0 billion.
Material Changes vs. Prior Period
Segment Performance:
- Diabetes Care: Turnover increased 6% to DKK 18.7 billion. Operating profit surged 32% to DKK 3.1 billion, driven by a 115% growth in insulin analogues.
- Biopharmaceuticals: Turnover increased 4% to DKK 7.8 billion. Operating profit decreased 10% to DKK 3.3 billion due to higher R&D spending, primarily for NovoSeven.
- Acquisitions: Completed acquisition of Biobras (Brazilian insulin company) in August 2003.
- Product Launches: Clinical proof of concept achieved for Liraglutide (NN2211) and NovoSeven in trauma patients. Received FDA Approvable Letter for insulin detemir (Levemir).
- Discontinuations: Suspended clinical trials for NN414 (beta-cell selective compound) in October 2003.
- Partnerships: Assumed U.S. marketing of Activella and Vagifem from Pfizer; settled dispute regarding early termination of marketing agreement.
- Currency Impact: Depreciation of main invoicing currencies negatively impacted reported sales and margins. Local currency sales growth was 15%.
- Cost Structure: Production costs rose 12% to 28% of net turnover. Non-production costs grew modestly by 2%.
Guidance, Outlook, and Risks
Outlook for 2004:
- Management expects R&D spending to remain approximately 16% of net turnover.
- Investments of DKK 3.0 billion planned for fixed assets, with a significant portion outside Denmark.
- Dividend proposal: DKK 4.40 per share.
- Patent Expirations: Activella/Activelle patents expire in the U.S. in 2006 and Europe in 2009. NovoSeven patent expires in Japan in 2008.
- Regulatory: Dependence on FDA and EMEA approvals. Negative market trends for hormone replacement therapy (HRT) due to health risk studies.
- Financial Risks: Foreign exchange sensitivity; a 5% weakening of DKK against all currencies would decrease fair value of financial positions by DKK 295 million.
- Off-Balance Sheet: Credit guarantee of up to 15% on sold trade debtors in Japan (DKK 44 million exposure in 2003).
- Minor positive non-recurring income expected in 2004 from the settlement of the Pfizer HRT dispute.
- Impairment of assets and inventory adjustments impacted gross margin.
Investor Verification Checklist
- Accounting Transition: Verify the impact of the transition from Danish GAAP to IFRS effective January 1, 2004, on asset valuation and equity.
- Currency Sensitivity: Assess the exposure to DKK fluctuations, as production costs are primarily in DKK while sales are global.
- R&D Pipeline: Monitor the progress of Liraglutide (obesity/diabetes) and insulin detemir (Levemir) approvals and commercialization.
- HRT Market Trends: Evaluate the long-term impact of declining HRT markets on the biopharmaceuticals segment.
- Patent Cliff: Review the timeline for patent expirations on Activella (2006/2009) and NovoSeven (Japan 2008).
- Capital Allocation: Confirm the execution of the DKK 3.0 billion investment plan for 2004, particularly outside Denmark.